Cartherics to File IND for Ovarian Cancer iPSC-Derived NK Cell Therapy CTH-401 After Asia Pacific Award

July 5, 2026

Cartherics Pty Ltd Australia

Overview

Australian biotech Cartherics Pty Ltd was recognized as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026. Leveraging its proprietary gene-edited induced pluripotent stem cell (iPSC) platform, Cartherics enables scalable manufacturing of off-the-shelf Natural Killer (NK) cell therapies. The company plans to submit an Investigational New Drug (IND) application later this year for a first-in-human clinical trial of its lead candidate, CTH-401, targeting ovarian cancer, underscoring its international leadership in allogeneic cell therapy development.

In Depth

Key Findings

Cartherics Pty Ltd, an Australian biotechnology company, has been distinguished as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026, marking international recognition for its innovative induced pluripotent stem cell (iPSC)-derived Natural Killer (NK) cell therapy development. The company is slated to submit an Investigational New Drug (IND) application later this year for a first-in-human clinical trial of CTH-401, its lead candidate targeting ovarian cancer.

Technical / Clinical Details

Cartherics’ gene-edited iPSC platform offers significant advantages:

Scalable Manufacturing: iPSCs possess indefinite self-renewal capabilities, allowing for the mass production of consistent NK cell lines. This enables the development of ‘off-the-shelf’ therapies that can be supplied to multiple patients, in contrast to autologous therapies that require patient-specific cell harvesting and manipulation.
Gene Editing for Enhanced Functionality: The platform incorporates precise gene-editing technologies designed to enhance the anti-tumor activity of NK cells and improve their persistence within the challenging tumor microenvironment. This is expected to maximize therapeutic efficacy.
CTH-401 Target: The lead candidate, CTH-401, is aimed at ovarian cancer, a disease with significant unmet medical needs and limited treatment options. The potential of iPSC-derived NK cell therapy to offer a new therapeutic modality for this difficult-to-treat malignancy is a key focus.

Background & Context

Allogeneic cell therapies are viewed as the next frontier in cell therapy, designed to overcome the manufacturing challenges (high cost, complex logistics, and variability in patient-derived cells) associated with autologous approaches. Advances in iPSC technology provide a scalable and uniform cell source for this allogeneic strategy, which is critical for accelerating the commercialization of cell therapies. Cartherics’ award highlights its leadership in driving innovation in this field across the Asia Pacific region.

Strategic Significance & Outlook

The planned IND submission for CTH-401 represents a crucial milestone in the clinical development of allogeneic iPSC-derived NK cell therapies. Successful progression through the initial human clinical trial could not only provide a new treatment option for ovarian cancer patients but also broaden the application of iPSC-derived NK cells to other solid tumors and hematological malignancies. This is a significant step towards improving the accessibility and efficacy of cell therapies on a global scale.

Source: https://cartherics.com/cartherics-recognised-as-asia-pacific-emerging-leader-in-allogeneic-cell-therapy/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.